Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1

被引：734

作者：

Hunder, Naomi N. ^{[1
]}

Wallen, Herschel ^{[1
]}

Cao, Jianhong ^{[1
]}

Hendricks, Deborah W. ^{[1
]}

Reilly, John Z. ^{[1
]}

Rodmyre, Rebecca ^{[1
]}

Jungbluth, Achim ^{[3
]}

Gnjatic, Sacha ^{[3
]}

Thompson, John A. ^{[2
]}

Yee, Cassian ^{[1
,2
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res New York Branch, New York, NY 10021 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2008年 / 358卷 / 25期

关键词：

D O I：

10.1056/NEJMoa0800251

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.

引用

页码：2698 / 2703

页数：6

共 20 条

[1] CROSS-PRIMING FOR A SECONDARY CYTOTOXIC RESPONSE TO MINOR H-ANTIGENS WITH H-2 CONGENIC CELLS WHICH DO NOT CROSS-REACT IN CYTOTOXIC ASSAY [J].

BEVAN, MJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) :1283-1288

[2]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[3] Adoptive immunotherapy for cancer: building on success [J].

Gattinoni, L ;

Powell, DJ ;

Rosenberg, SA ;

Restifo, NP .

NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393

[4] Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients:: Correlation with antibody responses [J].

Gnjatic, S ;

Atanackovic, D ;

Jäger, E ;

Matsuo, M ;

Selvakumar, A ;

Altorki, NK ;

Maki, RG ;

Dupont, B ;

Ritter, G ;

Chen, YT ;

Knuth, A ;

Old, LJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (15) :8862-8867

[5]

GREENBERG PD, 1991, ADV IMMUNOL, V49, P281

[6] THERAPY OF DISSEMINATED MURINE LEUKEMIA WITH CYCLOPHOSPHAMIDE AND IMMUNE LYT-1+,2- T-CELLS - TUMOR-ERADICATION DOES NOT REQUIRE PARTICIPATION OF CYTO-TOXIC T-CELLS [J].

GREENBERG, PD ;

KERN, DE ;

CHEEVER, MA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1122-1134

[7] The central role of CD4+ T cells in the antitumor immune response [J].

Hung, K ;

Hayashi, R ;

Lafond-Walker, A ;

Lowenstein, C ;

Pardoll, D ;

Levitsky, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368

[8] Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes [J].

Jäger, E ;

Chen, YT ;

Drijfhout, JW ;

Karbach, J ;

Ringhoffer, M ;

Jäger, D ;

Arand, M ;

Wada, H ;

Noguchi, Y ;

Stockert, E ;

Old, LJ ;

Knuth, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (02) :265-270

[9] Immunization of HLA-A*0201 and/or HLA-DPβ1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen [J].

Khong, HT ;

Yang, JC ;

Topalian, SL ;

Sherry, RM ;

Mavroukakis, SA ;

White, DE ;

Rosenberg, SA .

JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) :472-477

[10] IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response [J].

Li, YQ ;

Bleakley, M ;

Yee, C .

JOURNAL OF IMMUNOLOGY, 2005, 175 (04) :2261-2269

← 1 2 →